

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address CV MMISSIONER OF PATENTS AND TRADEMARKS PO Bev 1496 Verandra Vignia 223(3)(450 www.iupto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10 057,487	0 057.487 01 25 2002		Lisa A. Racie	08702.0073-00000 3565	
25291	7590	06 03 2003			
WYETH			EXAMINER		
PATENT LAW GROUP FIVE GIRALDA FARMS				SLOBODYANSKY, ELIZABETH	
MADISON, NJ 07940			ART UNIT	PAPER NUMBER	
				1652	1 .
				DATE MAILED: 06 03 2003	( /

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
		10/057,487	RACIE ET AL.					
	Office Action Summary	Examiner	Art Unit					
		Elizabeth Slobodyansky	1652					
	The MAILING DATE of this communication app		correspondence address					
Period fo								
THE I - Externanter - If the - If INC - Failu - Any rearne	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insigns of time may be available under the provisions of 37 CFR 1 13 SIX (6) MONTHS from the mailing date of this communication of period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a) In no event, however, may a reply be ti or within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS from c cause the application to become ABANDONI	mely filed ys will be considered timely n the mailing date of this communication. ED (35 U.S.C. § 133).					
Status	Decreasive to communication(s) filed on 1/1	Aarah 2002						
1)[X]	Responsive to communication(s) filed on 14 M	is action is non-final.						
2a)□	This action is <b>FINAL</b> . 2b) The Since this application is in condition for allowed		prosecution as to the merits is					
3)⊡ Dispositi	closed in accordance with the practice under to of Claims							
•	Claim(s) 1-27 is/are pending in the application	ı <b>.</b>						
	4a) Of the above claim(s) 1-13,15 and 17-27 is/are withdrawn from consideration.							
A	Claim(s) 14 and 16 is/are allowed.							
	Claim(s) is/are objected to.							
8)	Claim(s) are subject to restriction and/or	r election requirement.						
Applicati	on Papers							
9)[	The specification is objected to by the Examine	r.						
10)	The drawing(s) filed on is/are: a)☐ accep	oted or b) objected to by the Exa	aminer.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.								
12) The oath or declaration is objected to by the Examiner.								
-	under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a)[	☐ All b)☐ Some * c)☐ None of:							
	1. Certified copies of the priority documents							
	2. Certified copies of the priority documents							
* S	3. Copies of the certified copies of the prior application from the International Bu See the attached detailed Office action for a list	reau (PCT Rule 17.2(a)).						
14) 🗌 A	Acknowledgment is made of a claim for domesti	c priority under 35 U.S.C. § 119	(e) (to a provisional application).					
	<ul> <li>The translation of the foreign language pro Acknowledgment is made of a claim for domesting</li> </ul>							
Attachmen	t(s)							
2) Notic	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s) <u>6</u>	5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)					

Application/Control Number: 10/057,487 Page 2

Art Unit: 1652

#### **DETAILED ACTION**

The amendment filed March 14, 2003 (Paper No.9) amending claims 14 and 16 has been entered.

Claims 1-27 are pending.

### Election/Restriction

Applicant's election with traverse of Group V, claims 14 and 16, in Paper No.9 is acknowledged. The traversal is on the ground(s) that "The search and examination of this application do not constitute a serious burden because of the close relationship among the sequences" (Remarks, page 1). This is not found persuasive because it is unclear which specific Groups are discussed. As for the entire application, the inventions of separate Groups are independent and distinct for the reasons given previously in the Office action mailed February 19, 2003. "For purposes of the initial requirement, a serious burden on the examiner may be prima facie shown if the examiner shows by appropriate explanation either separate classification, separate status in the art, or a different field of search as defined in MPEP 808.02." (see MPEP 803).

The requirement is still deemed proper and is therefore made FINAL.

Claims 1-13, 15 and 17-27 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected Groups I-IV and VI-XII, there being

Application/Control Number: 10/057,487 Page 3

Art Unit: 1652

no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No.9.

## **Priority**

SEQ ID NO:8 is not disclosed in the parent application 09/978,979. Therefore, for the purposes of the prior art, the filing date of the instant application is its actual filing date of January 25, 2002.

# Specification

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825. 37 CFR 1.821(d) requires the use of assigned sequence identifier in all instances where the description or claims of a patent application discuss sequences. Figure 1 represents the nucleotide sequence without the sequencer identifier being used either in the drawing or in the Brief Description of the Drawings. Furthermore, for example, on pages 16, 19-22, 24, 25, the sequences are recited without references to the sequence identifiers.

Appropriate correction is required.

Application/Control Number: 10/057,487 Page 4

Art Unit: 1652

The following is an examiner's statement of reasons for allowance:

While Zheng et al. (November 2001) teach ADAMTS13 having the amino acid sequence of 1427 residues that differs from SEQ ID NO:8 by two substitutions W7R and A900Y, thorough searches of the prior art revealed no previous teaching or suggestion of an aggrecanase or any other protein having the amino acid sequence of SEQ ID NO:8.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

This application is in condition for allowance except for the following formal matters: 1. non-elected claims should be canceled. 2. the application must comply with the requirements of 37 CFR 1.821 through 1.825.

Prosecution on the merits is closed in accordance with the practice under *Ex* parte Quayle, 1935 C.D. 11, 453 O.G. 213.

A shortened statutory period for reply to this action is set to expire **TWO**MONTHS from the mailing date of this letter.

Art Unit: 1652

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth Slobodyansky whose telephone number is (703) 306-3222. The examiner can normally be reached Monday through Friday from 9:30 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Ponnathapura Achutamurthy, can be reached at (703) 308-3804. The FAX phone number for Technology Center 1600 is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Center receptionist whose telephone number is (703) 308-0196.

Elizabeth Slobodyansky, PhD

**Primary Examiner** 

May 29, 2003